A new study finds significant associations between antibodies for multiple oral bacteria and the risk of pancreatic cancer (Gut, September 18, 2012).
The study of blood samples from more than 800 European adults found that high antibody levels for one of the more infectious periodontal bacterium strains of Porphyromonas gingivalis were associated with a twofold risk for pancreatic cancer.
Meanwhile, study subjects with high levels of antibodies for some kinds of harmless "commensal" oral bacteria were associated with a 45% lower risk of pancreatic cancer.
"The relative increase in risk from smoking is not much bigger than two," said Brown University epidemiologist Dominique Michaud, PhD, the paper's corresponding author, in a university press release. "If this is a real effect size of two, then the potential impact of this finding is really significant."
Pancreatic cancer, which is difficult to detect and kills most patients within six months of diagnosis, is responsible for 40,000 deaths a year in the U.S.
Several researchers, including Michaud, have found previous links between periodontal disease and pancreatic cancer. The Gut paper is the first study to test whether antibodies for oral bacteria are indicators of pancreatic cancer risk and the first study to associate the immune response to commensal bacteria with pancreatic cancer risk. The physiological mechanism linking oral bacteria and pancreatic cancer remains unknown, but the study strengthens the suggestion that there is one, according to the researchers.
"This is not an established risk factor," said Michaud, who is also co-lead author with Jacques Izard, PhD, of the Forsyth Institute and Harvard University. "But I feel more confident that there is something going on. It's something we need to understand better."
Causal link suggested
For this study, the international research team drew on medical records and preserved blood samples collected by the Imperial College-led European Prospective Investigation into Cancer and Nutrition Study, a massive dataset of more than 500,000 adults in 10 countries. Detailed health histories and blood samples are available from more than 380,000 of the participants.
From that population, the researchers found 405 people who developed pancreatic cancer, but no other cancer, and who had blood samples available. The researchers also selected 416 demographically similar people who did not develop pancreatic cancer for comparison.
The researchers blinded themselves to which samples came from cancer patients and which didn't during their analysis of the blood, which consisted of measuring antibody concentrations for 25 pathogenic and commensal oral bacteria. In their study design and analysis, they controlled for smoking, diabetes, body mass index, and other risk factors.
An important element of the study design was that the date of the blood samples preceded the diagnosis of pancreatic cancer by as much as a decade, meaning that the significant difference in antibody levels were likely not a result of cancer.
Instead, the underlying mechanisms that link P. gingivalis to pancreatic cancer could be causal, Michaud said, although much more research is needed to understand this association.
The association of high levels of antibodies for commensal bacteria and pancreatic cancer may also indicate an innate, highly active immune response that is protective against cancer, the researchers noted.
"Genetic determinants of immune surveillance clearly play a critical role in pancreatic cancer development," they wrote. "Consequently, it is plausible that elevated levels of antibodies to oral bacteria in individuals serve as a marker for a genetically stronger immune response, providing protection against carcinogenesis."
The National Cancer Institute was the primary funder of the study.
